Literature DB >> 32623638

Restoration of euthyroidism in women with Hashimoto's thyroiditis changes bone microarchitecture but not estimated bone strength.

Maria Lohman Obling1,2, Pia Nicolaisen1,2, Thomas Heiberg Brix1, Kristian Hillert Winther1, Stinus Hansen3,4, Laszlo Hegedüs1, Anne Pernille Hermann1, Steen Joop Bonnema5,6.   

Abstract

PURPOSE: Fracture risk in hypothyroid patients is debated, and since the effects of hypothyroidism on bone microarchitecture and strength are unclarified, we investigated these characteristics by high-resolution peripheral quantitative computed tomography (HR-pQCT).
METHODS: Two approaches were used: a cross-sectional control study, comparing 32 hypothyroid women (mean age; 47 ± 12 years) suffering from Hashimoto's thyroiditis with 32 sex-, age-, and menopause-matched healthy controls; a prospective study, where 27 of the women were reexamined 1 year after restoration of euthyroidism. HR-pQCT of the distal radius and tibia, and dual-energy X-ray absorptiometry (DXA) of the spine and hip were performed. Bone strength was estimated using a finite element analysis (FEA).
RESULTS: Cross-sectional control study: in the radius, total (mean 14.6 ± 29.3% (SD); p = 0.04) and trabecular bone areas (19.8 ± 37.1%, p = 0.04) were higher, and cortical volumetric bone mineral density (vBMD) lower (-2.2 ± 6.5%, p = 0.032) in hypothyroid patients than in controls. All indices of tibia cortical and trabecular vBMD, microarchitecture, and estimated bone strength were similar between groups, as was hip and spine areal BMD (aBMD). Prospective study: in the radius, mean cortical (-0.9 ± 1.8%, p = 0.02) and trabecular (-1.5 ± 4.6%, p = 0.02) vBMD decreased, and cortical porosity increased (18.9 ± 32.7%, p = 0.02). In the tibia, mean total vBMD (-1.1 ± 1.9%, p = 0.01) and cortical vBMD (-0.8 ± 1.4%, p = 0.01) decreased, while cortical porosity (8.2 ± 11.5%, p = 0.002) and trabecular area (0.2 ± 0.6%, p = 0.047) increased. No changes in FEA were detected. Lumbar spine aBMD decreased (-1.3 ± 3.0%, p = 0.04).
CONCLUSIONS: Hypothyroidism was associated with an increased trabecular bone area and a lower mineral density of cortical bone in the radius, as assessed by HR-pQCT. Restoration of euthyroidism mainly increased cortical porosity, while estimated bone strength was unaffected.

Entities:  

Keywords:  Bone microarchitecture; HR-pQCT; Hypothyroidism; Levothyroxine

Mesh:

Year:  2020        PMID: 32623638     DOI: 10.1007/s12020-020-02398-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  4 in total

1.  The impact of thyroid autoimmunity (TPOAb) on bone density and fracture risk in postmenopausal women.

Authors:  Snezana P Polovina; Dragana Miljic; Sladjana Zivojinovic; Natasa Milic; Dragan Micic; Vera Popovic Brkic
Journal:  Hormones (Athens)       Date:  2017-01       Impact factor: 2.885

2.  Morphometric and dynamic studies of bone changes in hypothyroidism.

Authors:  L Mosekilde; F Melsen
Journal:  Acta Pathol Microbiol Scand A       Date:  1978-01

3.  Do premenopausal hypothyroid women on levothyroxine therapy need bone status monitoring?

Authors:  Ruby P Babu; Alap Christy; Anupama Hegde; Poornima Manjrekar; Vivian D'Souza
Journal:  Clin Med Insights Womens Health       Date:  2015-03-15

4.  Treatment of subclinical hypothyroidism does not affect bone mass as determined by dual-energy X-ray absorptiometry, peripheral quantitative computed tomography and quantitative bone ultrasound in Spanish women.

Authors:  Juan D Pedrera-Zamorano; Raul Roncero-Martin; Julian F Calderon-Garcia; Mercedes Santos-Vivas; Vicente Vera; Mariana Martínez-Alvárez; Purificación Rey-Sanchez
Journal:  Arch Med Sci       Date:  2015-10-12       Impact factor: 3.318

  4 in total
  1 in total

1.  Do bone turnover markers reflect changes in bone microarchitecture during treatment of patients with thyroid dysfunction?

Authors:  C J Vinther; L H Poulsen; P Nicolaisen; M L Obling; T H Brix; A P Hermann; L Hegedüs; N R Jørgensen; S Hansen; S J Bonnema
Journal:  J Endocrinol Invest       Date:  2022-09-05       Impact factor: 5.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.